InflammX Therapeutics, Inc

Industry

  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Drug Discovery Technologies
      • ADMET
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials

Other Names/Subsidiaries

  • CoDa Therapeutics, Inc. OcuNexus Therapeutics, Inc
See more in Biomedtracker

Latest on InflammX Therapeutics, Inc

Scrip

Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis

Scrip

Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy

 
• By Ian Haydock

Three-year-old US prescription eye care business Eyevance Pharmaceuticals LLC. has been acquired by Japan’s Santen Pharmaceutical Co., Ltd. , which gains a curated portfolio of commercialized produ

Scrip

Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials

 
• By Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Deal Should Help Gilead “Gly

Scrip

Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna

 
• By Joseph Haas, Brian Yang, Jo Shorthouse, and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Alexion Teams With Dicerna O